A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Journal of Health Economics and Outcomes Research
doi 10.36469/9820
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Columbia Data Analytics

Related search

Pharmacoeconomic Analysis of Brentuximab Vedotin Therapy in Relapsed or Refractory Cd30+ Systemic Anaplastic Large Cell Lymphoma in Patients Over 18 Years of Age: Health Budget Impact Analysis

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology
2017English

Prognostic Factors in Patients With Relapsed or Refractory Systemic Anaplastic Large T-Cell Lymphoma (Alcl) Receiving Brentuximab Vedotin and Outcome After Treatment Failure.

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Malignant tumours
2017English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy